NHS introduces Pfizer’s tafamidis for ATTR-CM treatment

14 May 2024
www.pharmaceutical-technology.com
Drug ApprovalAHA
NHS introduces Pfizer’s tafamidis for ATTR-CM treatment
Preview
Source: Pharmaceutical Technology
Tafamidis slows ATTR-CM’s progression by preventing the accumulation of protein deposits in the heart. Credit: Orawan Pattarawimonchai / Shutterstock.com
The UK’s National Health Service (NHS) has introduced Pfizer‘s tafamidis for transthyretin amyloidosis cardiomyopathy (ATTR-CM), a rare heart condition characterised by shortness of breath, fatigue, palpitations, fainting and chest pain.
The development comes after the National Institute of Health and Care Excellence (NICE) approved the treatment for ATTR-CM patients in the country.
The drug significantly reduces hospitalisation and mortality risks for patients.
The once-a-day capsule slows the progression of ATTR-CM by preventing the accumulation of protein deposits in the heart.
Clinical trials have demonstrated a 41% decline in mortality risk among patients treated with tafamidis versus those on a placebo.
See Also:UK Government expands opioid overdose treatment access
NHS introduces Pfizer’s tafamidis for ATTR-CM treatment
Preview
Source: Pharmaceutical Technology
Shionogi secures licence for Maze’s Pompe disease treatment
NHS introduces Pfizer’s tafamidis for ATTR-CM treatment
Preview
Source: Pharmaceutical Technology
The NHS’s decision to offer tafamidis is underpinned by interim funding from the Innovative Medicines Fund, making the treatment accessible to more than 1,000 eligible patients in England.
NHS England heart disease national clinical director professor Simon Ray stated: “A first of its kind, tafamidis will give those living with this rare progressive condition new hope – with NHS patients now able to benefit from a once-a-day treatment that can reduce the risk of hospitalisation and heart failure.
“This pioneering drug is just one example of the NHS delivering on its commitment to ensure patients across the country have access to the latest and most effective treatments to help significantly improve their quality of life.”
Before the introduction of tafamidis, treatment options for ATTR-CM were primarily limited to managing symptoms and providing supportive care.
Pfizer UK country president Susan Rienow stated: “This positive NICE decision, and interim funding through the Innovative Medicines Fund, is a significant milestone for eligible patients.
“We’ve remained committed to ensuring access to tafamidis and we’re pleased that it will now be available across the UK.”
This month, the NHS announced plans to offer Pfizer‘s Voxelotor (Oxbryta), a new treatment option for sickle cell disease patients.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.